ライフサイエンスコーパス: risk reduction

1 e (5.7% and 8.3%, respectively; 32% relative risk reduction).

2 ve effect on the risk of brain injuries (34% risk reduction).

3 confidence interval: -0.3% to 4.6%) absolute risk reduction.

4 s an indicator of treatment-related fracture risk reduction.

5 rd a new strategy for lipid-lowering and CVD risk reduction.

6 cified minimal clinically important relative risk reduction.

7 open a new avenue for cardiovascular disease risk reduction.

8 be aggressively targeted for cardiovascular risk reduction.

9 s of statin-dependent cardiovascular disease risk reduction.

10 tes medications did not confer a similar OAG risk reduction.

11 radiation provides an absolute locoregional risk reduction.

12 owing interest in nature-based solutions for risk reduction.

13 eta-blockers was associated with the largest risk reduction.

14 tiative study was used to calculate inferred risk reduction.

15 r a potential public health strategy for CVD risk reduction.

16 ntribution of ecosystem services to disaster risk reduction.

17 AP treatment may be beneficial for metabolic risk reduction.

18 ns aimed at breast density and breast cancer risk reduction.

19 ns have been associated with cardiometabolic risk reduction.

20 ussions of sexual development, behavior, and risk reduction.

21 prophylaxis and individualized counseling on risk reduction.

22 .3 (95% CI, .01-3.1), corresponding to a 70% risk reduction.

23 and event rates along with trial-based event risk reduction.

24 and hs-cTnI identify candidates for targeted risk reduction.

25 ve CAD, may represent a novel target for CVD risk reduction.

26 treatment, with or without a 20% behavioral risk reduction.

27 e sessions to train their network members in risk reduction.

28 les and checklists appears to yield stronger risk reductions.

29 cantly reduced that risk with large absolute risk reductions.

30 gnificantly the risk for infection (relative risk reduction = 0.33; 95% CI, .03,4.28).

31 n in nonfatal MI benefit persisted (absolute risk reduction, 0.15 to 1.43 events per 1000 person-year

32 tion, 6.7% [95% CI, 1.2% to 13.6%]; absolute risk reduction, 0.46% [CI, 0% to 0.9%]).

33 azard ratio [HR], 0.73 [0.65-0.83]; absolute risk reduction, 0.63% [0.36%-0.92%]; P < .01).

34 ients who did not undergo ablation (relative risk reduction: 0.08; 95% confidence interval: 0.02 to 0

35 ients who did not undergo ablation (relative risk reduction: 0.08; 95% confidence interval: 0.02 to 0

36 , which was lower than expected (ie, greater risk reduction); 1.01 (95% CI, 0.94-1.09) vs 0.90 (95% C

37 admissions for phototherapy by 53% (absolute risk reduction, 1.8%; 95% CI, 1.4%-2.3%).

38 nt therapy (7 [5.8%] vs 19 [15.8%]; absolute risk reduction, 10%; 95% CI, 2.25%-17.75%; P = .01), and

39 nts [50.5%] vs 37 [35.6%]; P = .02; absolute risk reduction, 14.9; 95% CI, 1.4 to 28.2).

40 ontrol (63 of 120 patients [52.5%]; absolute risk reduction, 15%; 95% CI, 2.56%-27.44%; P = .02).

41 cause (RR, 0.91; 95% CI, 0.85-0.97; absolute risk reduction, 2.6%; P=0.003).Cancer incidence was simi

42 ds ratio = 0.31; 95% CI, 0.16-0.61; absolute risk reduction = 28%; 95% CI, 12-42).

43 etinal-detachment surgery, or both (adjusted risk reduction, 45%; 95% CI, 12 to 66; P=0.01).

44 n the control group (5.2% vs. 9.8%; relative risk reduction, 46.3% [95% confidence interval, 6.8 to 6

45 .31-87.25) of patients in the placebo group (risk reduction 5.05%; hazard ratio 0.95, 95% CI 0.80-1.1

46 ospitalizations was reduced by 59% (absolute risk reduction, 5.5%; 95% CI, 4.7%-6.1%) and readmission

47 ast 1 reoperation within 12 months (relative risk reduction, 59%; relative risk, 0.41 [95% CI, 0.23 t

48 mortality and all-cause mortality (relative risk reduction, 6.7% [95% CI, 1.2% to 13.6%]; absolute r

49 isk [RR], 0.84 [95% CI, 0.71-1.01]; absolute risk reduction, 6.8% [95% CI, -0.3% to 13.9%]; P = .07).

50 observed in humans and demonstrated the same risk reduction (70%) previously attained in women with h

51 om 19.9% to 11.5% (P < 0.001), with absolute risk reduction 8.4 (95% confidence interval, 6.3-10.5) f

52 (5% vs 33%; chi21 = 11.1; P < .001; relative risk reduction, 84.7%).

53 hieved clinically significant cardiovascular risk reduction (a weight loss >/=5% or an increase of >5

54 t gradient (p=0.0277) of increasing relative risk reductions across the low (13%), intermediate (29%)

55 ality, reaching a plateau with more than 50% risk reduction after an administration-to-birth interval

56 0.41, 95% CI 0.26-0.65) had significant VTE risk reduction after surgery with chemoprophylaxis.

57 ]), statin therapy led to a greater relative risk reduction among a subgroup at high genetic risk.

58 scribe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associ

59 ultural priorities in international disaster risk reduction and adaptation efforts.

60 ng pregnancy is necessary for evidence-based risk reduction and adequate patient counseling.

61 ular infections, physicians should regard on risk reduction and comply with etiologic approach of dia

62 native readmission metrics in strategies for risk reduction and cost savings.

63 ity economic externalities, and the value of risk reduction and pure health gains.

64 We also estimated the potential risk reduction and residual risk that can be achieved if

65 associated with greater total cardiovascular risk reduction and specifically for myocardial infarctio

66 dations for mild asthma should consider both risk reduction and symptoms.

67 e (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%

68 2), which was higher than expected (ie, less risk reduction); and 0.49 (95% CI, 0.34-0.71) vs 0.61 (9

69 cagrelor reduced MACE, with a large absolute risk reduction, and MALE.

70 illness have reported clinically significant risk reduction, and none have been replicated in communi

71 ions, although the magnitude of the ischemic risk reduction appeared to be enhanced with prasugrel.

72 , and continued attention and strategies for risk reduction are needed.

73 se in the lowest subgroup had no significant risk reduction (ARR = 0.006, 95% CI: -0.007, 0.018; P =

74 isk [RR], 0.87; 95% CI, 0.78-0.96); absolute risk reduction (ARR) in events per 1000 patient-years (3

75 The primary outcome was absolute risk reduction (ARR) in morbidity (defined by Clavien-Di

76 onfidence interval (CI), 1.81-2.10; absolute risk reduction (ARR), 6.37%].

77 f the relative hazard reduction and absolute risk reduction (ARR).

78 g a model to predict individualized absolute risk reductions (ARR) of cardiovascular events.

79 epeated self-harm (0.84, 0.77-0.91; absolute risk reduction [ARR] 2.6%, 1.5-3.7; numbers needed to tr

80 ent 1 CVD event/death over 5 years (absolute risk reduction [ARR] = 0.042, 95% CI: 0.018, 0.066; P =

81 [OR], 1.62 [95% CI, 1.31 to 2.00]; absolute risk reduction [ARR] in events per 100 infants, -12.0 [9

82 ically significant (12.9% vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confiden

83 (20.2%) died during their ICU stay (absolute risk reduction [ARR], 0.086 [95% CI, 0.017-0.150]; relat

84 are strategies by measuring effectiveness of risk reduction as a function of the features of projecte

85 ontrol, and likely to cardiovascular disease risk reduction, as statins have been over the past three

86 For all outcomes, the risk reduction associated with ANS was transient, with i

87 omorbidity burden (2 and >/=3), the absolute risk reduction associated with CRT-D over ICD alone appe

88 highest range of body mass index (BMI), the risk reduction associated with preoperative weight loss

89 P in predicting incident CKD and whether CKD risk reduction associates with progressive treatment-ind

90 The inferred HIV risk reduction, based on PBMC TFV-DP concentration, reac

91 cluding prevention products, procedures, and risk-reduction behaviours) into population-level effects

92 gher lipids were associated with greater CVD risk reduction benefits from intensive treatment, while

93 e 100 million or more people who may receive risk reduction benefits from reefs or bear hazard mitiga

94 l for atherosclerotic cardiovascular disease risk reduction benefits, adverse effects, drug-drug inte

95 There were no significant differences in risk reduction between the TAU and screening phases (23%

96 edicted benefit had significant absolute CVD risk reduction, but the overall ACCORD-BP participant sa

97 ed therapies contributes importantly to this risk reduction, but there is still room for improvement.

98 was the first large randomized trial of CVD risk reduction by community pharmacists, demonstrating a

99 High-intensity counseling on sexual risk reduction can reduce STIs in primary care and relat

100 The RxEACH (Alberta Vascular Risk Reduction Community Pharmacy Project) study was a r

101 t cause sudden infant death, the mainstay of risk reduction continues to be a safe sleep environment,

102 Instead, risk reduction correlated with antibodies recognizing ep

103 All participants received risk-reduction counseling and condoms and were regularly

104 No consistent evidence was found that sexual risk-reduction counseling was harmful.

105 and STI knowledge, diagnosis, treatment, and risk reduction counselling can potentially reduce HIV an

106 A regression formula for HIV risk reduction derived from PBMCs collected in the preex

107 timates of coronary heart disease and stroke risk reduction due to antihypertensive medication treatm

108 al, 0.31-0.72; P < 0.001) with a significant risk reduction during the second year of follow-up (haza

109 Together, the studies quantify the risk reduction ecosystem services of marsh wetlands.

110 of Kaplan-Meier risk estimates and relative risk reduction estimates from previous trials.

111 ce of hypertension accounted for the largest risk reduction, followed by a reduction in tobacco smoki

112 Absolute risk reduction for a population with 2.5% incidence of p

113 Absolute risk reduction for a population with 5.4% incidence of e

114 The absolute risk reduction for acquiring a hospital-acquired infecti

115 d plasma lutein/zeaxanthin score, we found a risk reduction for advanced AMD of about 40% in both wom

116 This study estimated the relative risk reduction for CAD and mortality by statins in heter

117 No significant risk reduction for hospitalizations with injury diagnose

118 The absolute risk reduction for MV with HFNC was 29.8%, and the numbe

119 are needed to quantify sirolimus-associated risk reduction for other cancer types.

120 results were sensitive to alterations in the risk reduction for post-myocardial infarction events fro

121 Mendelian randomization analysis, the causal risk reduction for T2D was estimated to be 42% (causal O

122 e results in the experimental arm showed the risk reduction for the main end point to be < 9.64%.

123 ng serum urate levels may not translate into risk reductions for cardiometabolic conditions.

124 We used the relative risk reductions for the addition of a nonstatin to lower

125 risk, patients with PAD had larger absolute risk reductions for the primary end point (3.5% with PAD

126 ompleted statin trials show greater relative risk reductions for those patients at lower levels of ab

127 d targets was estimated by applying relative risk reductions from meta-analyses to the estimated risk

128 where appropriate, aligning conservation and risk reduction goals.

129 d against recent diabetes and cardiovascular risk reduction guidelines.

130 of 60 ml/min per 1.73 m(2) experienced a 12% risk reduction (hazard ratio [HR], 0.88; 95% confidence

131 h ADHD, medication was associated with a 58% risk reduction (hazard ratio, 0.42; 95% CI, 0.23-0.75),

132 th 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group,

133 nd from other partners, the magnitude of the risk reduction he would gain with PrEP, and nonpharmacol

134 vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7%

135 ne eGFR of 45 ml/min per 1.73 m(2) had a 13% risk reduction (HR, 0.87; 95% CI, 0.78 to 0.98).

136 se of agranulocytosis, based on the possible risk reduction if all three SNPs are genotyped and carri

137 tion significantly reduced the 12-mo overall risk (reduction in overall risk: -19%; 95% CI, -7 to -41

138 evelopment of preventive measures for injury risk reduction in adult patients with eczema.

139 t of dyslipidemia for cardiovascular disease risk reduction in adults.

140 n adjusted 32% (HR, 0.68; 95% CI, 0.47-0.98) risk reduction in all cancer-related deaths and a 68% re

141 .87, 0.79-0.96; p=0.007), and a 12% relative risk reduction in all-cause mortality (0.88, 0.81-0.95;

142 represented an intervention effect (absolute risk reduction in antibiotic prescribing) of -29% (95% C

143 tors; 20% of population) had a 3.2% absolute risk reduction in cardiovascular disease/MI/ischemic str

144 ted Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents of the Nation

145 ted Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents," several med

146 I2 = 49.0%) (n = 876) showed no significant risk reduction in compulsory admissions.

147 77; 95% CI, 0.60-0.98; I2 = 2.2%) (n = 1102) risk reduction in compulsory admissions.

148 confidence interval: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezeti

149 py with defibrillator, with greater absolute risk reduction in death and HF among those with moderate

150 rehensive approach to cardiovascular disease risk reduction in HIV-infected patients with DM and meas

151 U setting, we found a 26% (SD, 23%) relative risk reduction in length of stay with these intervention

152 The relative risk reduction in MACE with ticagrelor was consistent fo

153 Whereas the relative risk reduction in MACE with ticagrelor was consistent, r

154 The absolute risk reduction in mortality associated with dynamic asse

155 e bundles was associated with a 25% relative risk reduction in mortality rate.

156 pt of AET was associated with a 29% relative risk reduction in mortality.

157 isk elevation in WHI and in the direction of risk reduction in NHS.

158 mple sizes needed to detect a 5-10% absolute risk reduction in outcomes within interventional trials

159 rathyroidectomy was associated with fracture risk reduction in patients regardless of whether they sa

160 y beta-blocker associated with a significant risk reduction in patients with LQT2.

161 ific, Marlborough, Massachusetts) for stroke risk reduction in patients with nonvalvular AF at multip

162 llator provided the greatest HF or mortality risk reduction in patients with SBP<110 mm Hg hazard rat

163 ransfusion was associated with 3.5% absolute risk reduction in postoperative myocardial infarction.

164 with edoxaban resulted in a greater absolute risk reduction in severe bleeding events and all-cause m

165 This study demonstrated a 57% risk reduction in the chance for developing ALS in peopl

166 [CI], 0.85 to 1.20; P=0.90), for an absolute risk reduction in the EGDT group of -0.3 percentage poin

167 Risk reduction in the IAI groups for a sustained IOP inc

168 showed a clinically relevant and significant risk reduction in the pirfenidone group compared with th

169 Absolute risk reduction in the RT arm was 12.0% at 20 years (95%

170 treatment showed a significant 10% relative risk reduction in the three-point major adverse cardiova

171 chemoprevention highlights the potential for risk reduction in this population.

172 OT, and JUPITER primary prevention, relative risk reduction in those at high genetic risk was 46% ver

173 lnerable to making first attempts and target risk reduction in those groups.

174 analysis showed a significant cardiovascular risk reduction in those who used CPAP for >/=4 versus <4

175 of ACDs was associated with a 0.40% absolute risk reduction in vascular access site complications (95

176 y associated with incident AF with a greater risk reduction in women (hazard ratio per SD, 0.86; 95%

177 ervention to promote safe HIV disclosure and risk reduction in women seeking HIV counselling and test

178 relationship between the exercise volume and risk reductions in cardiovascular morbidity and mortalit

179 then investigated the relative and absolute risk reductions in coronary heart disease events with st

180 here was no clear evidence that proportional risk reductions in major cardiovascular disease differed

181 Similarly, we noted greater absolute risk reductions in those individuals in higher genetic r

182 ent cancer in unsuspecting relatives through risk-reduction intervention in mutation carriers and to

183 Culturally specific risk reduction interventions for Hispanic women should f

184 idence is lacking about the effectiveness of risk reduction interventions in patients with asymptomat

185 independent of the agents used, significant risk reduction is found at all hypertension grades (stag

186 ucation on postresection risk assessment and risk reduction is needed.

187 ich has the goals of fracture prevention and risk reduction, is moving beyond traditional monotherapi

188 iveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140/90

189 The Cardiovascular Risk Reduction Model was developed by Million Hearts and

190 o evaluate the Million Hearts Cardiovascular Risk Reduction Model.

191 Although risk reductions observed in randomized trials have been

192 d by total estrogen levels, with the largest risk reductions occurring in women in the highest tertil

193 Based on these results, an absolute risk reduction of 0.15 (15%), a relative risk reduction

194 ute risk reduction of 0.15 (15%), a relative risk reduction of 0.75 (75%) and a number needed to trea

195 val, 0.92-0.97; P < 0.001), with an absolute risk reduction of 1.4 per 100 person-years.

196 ing of SSBs with water was associated with a risk reduction of 10% (HR: 0.90; 95% CI: 0.85, 0.95).ASB

197 .4% in the home oxygen alone group, absolute risk reduction of 17.0% (95% CI, 0.1%-34.0%).

198 e attempt risk (23% vs 18%), with a relative risk reduction of 20%.

199 lyses on shunt dependency showed an absolute risk reduction of 24% for the intervention (LD, 2.2% [1

200 n vs 205 [19%] of 1055 for control, absolute risk reduction of 3.46%, 95% CI 0.21-6.73%, p=0.038) By

201 e, the high compliance group had an absolute risk reduction of 3.6% (P < 0.01), 2.9% (P < 0.01) and 1

202 years (95% CI, 6.5 to 17.7), with a relative risk reduction of 37.5%.

203 AD, patients with PAD had a greater absolute risk reduction of 4.1% (number needed to treat: 25) due

204 7.8% (95% CI: 2.4, 12.3), corresponding to a risk reduction of 4.2% (95% CI: 0.3, 8.1) and a preventa

205 lihood of vasovagal syncope by the specified risk reduction of 40%.

206 tatin therapy was associated with a relative risk reduction of 44% (95% confidence interval [CI], 22-

207 in the placebo group, a significant relative risk reduction of 44%.

208 of absolute decrease of 1.3%, and a relative risk reduction of 47.5% (95% CI, 44.1%-50.8%).

209 with water was associated with a significant risk reduction of 5% (HR: 0.95; 95% CI: 0.91, 0.99), whe

210 Based on previously reported data (relative risk reduction of 50%), the incremental gain in quality-

211 f protein associated with a maximum relative risk reduction of 62.4% (95% CI, 33.1 to 78.9; P<0.01).

212 k of recurrence and demonstrated an absolute risk reduction of 8.6% for stroke of any etiology (10.2%

213 Statins were associated with a risk reduction of 9% for bleeds (hazard ratio = 0.91, 95

214 A total risk reduction of 91% was observed in this group over 24

215 as it was approved by Health Canada for the risk reduction of CDAD in hospitalized patients.

216 ed trial that demonstrated an 11.7% absolute risk reduction of clinically significant POPF with use o

217 nary event, or nonfatal stroke, the relative risk reduction of combination therapy compared with mono

218 r there was a 7% absolute and a 24% relative risk reduction of death and dependency in the coiling gr

219 The absolute risk reduction of death from prostate cancer at 13 years

220 e exact 95% confidence interval for absolute risk reduction of fire ignition was 76% to 100%.

221 0.25-0.97) was associated with a significant risk reduction of HCC, while insulin (RR = 2.44, 95% CI

222 es every day was associated with the largest risk reduction of heart failure.

223 however, there is a consistent 15% relative-risk reduction of nonfatal myocardial infarction.

224 Force issued a guideline on medications for risk reduction of primary breast cancer in women.

225 Risk reduction of progression to T2DM by level of attend

226 or morbidity outcome, whereas a significant risk reduction of severe neonatal brain injury was assoc

227 This translated to relative risk reductions of 11.1% (P = .04), 12.6% (P = .02), and

228 The absolute risk reductions of COPD-related rehospitalization in the

229 ll lead to greater understanding of specific risks, reduction of exposures, and improvement of health

230 it approach (ie, based on predicted absolute risk reduction over 10 years [ARR10] >/=2.3% from random

231 -2 risk indicators; 61%) had a 2.1% absolute risk reduction (P<0.001 each), translating to a number n

232 suggest about a 15% cardiovascular relative risk reduction per 1% decrement in HbA1c.

233 c251, resulting in a vaccine efficacy (i.e., risk reduction per exposure) of 68%.

234 Similar proportional risk reductions (per 10 mm Hg lower systolic blood press

235 Moreover, the risk reduction potential of foods was calculated by mult

236 disciplinary cardiac rehabilitation (CR) and risk reduction program is an essential component of ASCV

237 effect of a rigorous cardiovascular disease risk reduction program on peripheral blood gene expressi

238 have examined the effect of a comprehensive risk-reduction program on long-term outcomes for patient

239 A guideline-recommended risk-reduction program targeted at patients with PAD was

240 Few comprehensive cardiovascular risk reduction programs, particularly those in rural, lo

241 Absolute risk reduction progressively increases higher is total c

242 Meta-regression analyses showed relative risk reductions proportional to the magnitude of the blo

243 Overall risk reduction (random-effects estimate) was calculated

244 r-sexual provisioning, kin provisioning, and risk reduction reciprocity, three levels of cooperation

245 ] in group 2; P<0.001), showing 45% relative risk reduction (relative risk, 0.55; 95% confidence inte

246 ognosis (and driver an effective therapeutic risk reduction) remains one of the greatest ongoing deba

247 Moreover, the degree of risk reduction seems to be related to amount of weight l

248 The development of effective risk reduction strategies for aquatic pollutants require

249 to guide patient education about lymphedema risk reduction strategies for those who undergo bilatera

250 t future episodes by developing personalized risk reduction strategies including, where possible, com

251 Alternate management or incremental risk reduction strategies may be needed in such patients

252 If such associations exist, additional risk reduction strategies may be needed.

253 cation with sexual partners especially about risk reduction strategies, including preexposure prophyl

254 erral after AKI, and help generate potential risk reduction strategies.

255 e largely contained using effective disaster risk reduction strategies.

256 ighlighting the importance of cardiovascular risk reduction strategies.

257 n elevated risk that would benefit most from risk-reduction strategies based on altering modifiable f

258 c complications in the setting of randomized risk-reduction strategies.

259 es were at higher risk of MACE, the absolute risk reduction tended to be greater in patients with ver

260 ector and adopting an ecological approach to risk reduction that addresses personal, societal, and cu

261 ndomized trials on relative and absolute CVD risk reduction that can occur when antihypertensive trea

262 or-positive first breast cancer, an absolute risk reduction that is consistent with findings from cli

263 Costs for stroke risk reduction therapies, treatment of associated acute

264 th et al, "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Ot

265 ical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied

266 RIM-3 trial, vemurafenib was associated with risk reduction versus dacarbazine of both death and prog

267 t 25, 2011, cladribine was associated with a risk reduction versus placebo for time to conversion to

268 acological therapy (n = 5,960), the absolute risk reduction was 1.9% with a 3-year number needed to t

269 047) compared with placebo, and the absolute risk reduction was 2.1 per 100 person-years.

270 <0.001), whereas in all others, the relative risk reduction was 24% (95% CI, 8-37; P=0.004) despite s

271 Risk reduction was 25% to 31% for women aged 50 to 69 ye

272 Absolute risk reduction was 32.3%, with a number needed to treat

273 The absolute risk reduction was 9.8% (95% CI, 8.2% to 18.9%), with a

274 We hypothesized that risk reduction was higher for infection-related cancer a

275 The magnitude of this risk reduction was modified by increases in total proced

276 The risk reduction was more apparent in younger people and i

277 ion phase (HR, 0.55; 95% CI, 0.34-0.89), but risk reduction was not observed during the late postinte

278 In contrast, a substantial risk reduction was observed among individuals who engage

279 The greatest level of risk reduction was observed for obese patients and for l

280 This risk reduction was observed only among persons who had a

281 Risk reduction was significantly larger in the diabetic

282 eved from aerobic exercise, the magnitude of risk reduction was similar regardless of intensity of ae

283 Absolute risk reductions were 25% (95% CI 6-41) for low-dose vers

284 disease, for which smaller, but significant, risk reductions were detected.

285 Similarly, however, less pronounced risk reductions were found when comparing patients in th

286 Risk reductions were most apparent among women whose pri

287 The largest risk reductions were observed for 4 cups/day for all-cau

288 nalyzed complications, whereas corresponding risk reductions were only occasionally encountered and l

289 Risk reductions were slightly smaller for past users but

290 pressures and heart failure hospitalization risk reduction with a novel implantable PA pressure moni

291 hese patients did not have a significant VTE risk reduction with chemoprophylaxis.

292 esults have shown unequivocal cardiovascular risk reduction with glucose lowering.

293 to investigate potential mediators of cancer risk reduction with immediate cART.

294 rapy underwent cataract extraction (adjusted risk reduction with intensive therapy, 48%; 95% CI, 23 t

295 The magnitude of relative risk reduction with rosuvastatin was similar among parti

296 Relative risk reduction with statin therapy has been consistent a

297 Across all 3 studies, the absolute risk reduction with statin therapy was 3.6% (95% CI, 2.0

298 In the setting of multifactorial risk reduction with statins and other lipid-lowering age

299 l hemorrhage (ICH) and the benefit of stroke risk reduction with the use of oral anticoagulants for p

300 We identified similar relative risk reductions with LMWH for individual outcomes, inclu